Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | OGT | O15294 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26156421 | 0.96 | CYP19A1 (0.45) | CYP19A1NPC1RAB9ABCHEPTGS2 | |
| SCHEMBL20995389 | 0.85 | CYP19A1 (0.47) | CYP19A1NPC1RAB9ABCHEPTGS2 | |
| SCHEMBL25494292 | 0.83 | FLT3 (0.46) | NPC1RAB9APTGS2PTGS1CA12 | |
| SCHEMBL20812240 | 0.83 | PTGS2 (0.47) | NPC1RAB9APTGS2PTGS1CA1 | |
| SCHEMBL20995378 | 0.83 | CYP19A1 (0.46) | CYP19A1NPC1RAB9ABCHEPTGS2 | |
| SCHEMBL22821490 | 0.82 | CYP19A1 (0.46) | CYP19A1NPC1RAB9ABCHEPTGS2 | |
| SCHEMBL21470628 | 0.81 | MIF (0.51) | LMNAEPHB4KDRDPP4TEK | |
| SCHEMBL15835844 | 0.81 | CHRNB2 (0.47) | CA12CA9KMT2A | |
| SCHEMBL22530587 | 0.80 | P2RY14 (0.49) | NPC1RAB9A | |
| SCHEMBL14212096 | 0.80 | STIM1 (0.51) | NPC1RAB9ATSHRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | GLYCOMIMETICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | GLYCOMIMETICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | GLYCOMIMETICS, INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | GLYCOMIMETICS, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200282016-A1 | Endoparasitic Depsipeptides | ZOETIS SERVICES LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200171005-A9 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker | GLYCOMIMETICS, INC. (US) | 2020-06-04 | — | — | US | disclosed |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2020-04-30 | — | — | US | disclosed |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | GLYCOMIMETICS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-9670247-B2 | Contraceptive agents | THE UNIVERSITY OF KANSAS (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670247-B2 | Contraceptive agents | THE UNIVERSITY OF KANSAS (US) | 2017-06-06 | — | — | US | disclosed |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | UNIVERSITÀ DI PISA (IT) | 2012-12-06 | — | — | US | disclosed |
| US-7834034-B2 | Benzothiophene derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090082308-A1 | Benzothiophene derivatives | MERCK SHARP & DOHME LLC | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399301-A1 | HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTIN AND GALECTIN-3 | LGALS3, LGALS3BP, LGALS1 | CYP19A1 4874/4885NPC1 2287/4885RAB9A 2221/4885 |
| US-20200282016-A1 | Endoparasitic Depsipeptides | VIP, PREP, NGLY1 | CYP19A1 1564/4885NPC1 893/4885RAB9A 549/4885 |
| US-20190233458-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | CYP19A1 4694/4885NPC1 1616/4885RAB9A 2792/4885 |
| US-20230218649-A1 | COMPOSITIONS AND METHODS FOR OVERCOMING MICROENVIRONMENT-MEDIATED RESISTANCE VIA E-SELECTIN TARGETING | SELE, SELPLG, MCL1 | CYP19A1 4504/4885NPC1 3495/4885RAB9A 3687/4885 |
| US-20120309794-A1 | COMPOUNDS INHIBITORS OF ENZYME LACTATE DEHYDROGENASE (LDH) AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LDHA, LDHB, DLD | CYP19A1 1141/4885NPC1 1519/4885RAB9A 2969/4885 |
| US-20230364277-A1 | E-SELECTIN TARGETING AGENTS | SELE, SELPLG, SELP | CYP19A1 4768/4885NPC1 1147/4885RAB9A 1624/4885 |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | FLT3, SELE, SELL | CYP19A1 3803/4885NPC1 3908/4885RAB9A 2773/4885 |
| US-20200171005-A9 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker | SELE, SELP, SELPLG | CYP19A1 3099/4885NPC1 3845/4885RAB9A 2678/4885 |
| US-11780873-B2 | Highly potent multimeric e-selectin antagonists | SELE, SELP, SELPLG | CYP19A1 4399/4885NPC1 1052/4885RAB9A 2841/4885 |
| US-20200129536-A1 | GALACTOPYRANOSYL-CYCLOHEXYL DERIVATIVES AS E-SELECTIN ANTAGONISTS | SELE, SELPLG, SELP | CYP19A1 4452/4885NPC1 1257/4885RAB9A 3759/4885 |
| US-20090082308-A1 | Benzothiophene derivatives | BRDT, HDAC5, BRPF3 | CYP19A1 899/4885NPC1 4239/4885RAB9A 4789/4885 |
| US-20230365609-A1 | HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS | SELE, SELP, SELPLG | CYP19A1 4694/4885NPC1 1616/4885RAB9A 2792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.